Section Arrow
INMB.NASDAQ
- INmune Bio
Quotes are at least 15-min delayed:2026/07/19 11:30 EDT
Regular Hours
Last
 1.9
-0.17 (-8.21%)
Day High 
2.07 
Prev. Close
2.07 
1-M High
2.165 
Volume 
802.92K 
Bid
1.95
Ask
2.09
Day Low
1.85 
Open
2.07 
1-M Low
1.28 
Market Cap 
55.03M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.86 
20-SMA 1.67 
50-SMA 1.5 
52-W High 3.244 
52-W Low 1.09 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.63/-0.44
Enterprise Value
55.44M
Balance Sheet
Book Value Per Share
0.74
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
50.00K
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ATAIAtaiBeckley Inc7.22+0.07+0.98%-- 
JSPRJasper Therapeutics0.885+0.111+14.34%-- 
LIMNLiminatus Pharma Inc0.123-0.0247-16.72%-- 
IOVAIovance Biotherapeutics5+0.34+7.30%-- 
RXRXRecursion Pharmaceuticals2.945-0.075-2.48%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.